Stocks In Action: Tyler Technologies, Inc. (NYSE:TYL), Electronic Arts Inc. (NASDAQ:EA), Pacific Biosciences of California (NASDAQ:PACB)
Dallas, Texas, 09/24/2014 (ustrademedia) – Tyler Technologies, Inc. (NYSE:TYL) recently inked a contract with the Assessments Division, city of Detroit’s Finance Department for its CLT Appraisal Services. The company will provide real property appraisal data verification, valuation and sketch conversion services. The contract is valued at $7 million. The city hasn’t completed a comprehensive reappraisal of its real properties in more than five decades and hence it executive a competitive ‘Request for Proposal’ process to seek experienced vendor to conduct an appraisal study. The project also involves the creation of digital property sketches. Tyler is the only mass appraisal services company in the country and has appraised over 30 million parcels in 46 states.
Electronic Arts Inc. (NASDAQ:EA) announced the availability of EA SPORTS™ FIFA 15 in retail stores throughout North America. The worldwide releases of the game are scheduled later this week. More than 5.5 million fans from across the world have played the demo of FIFA 15 across several platforms including gaming consoles like Xbox One, Xbox 360, PlayStation 3, PlayStation 4 and PC. FIFA 15 is designed to offer stunning visual detail to allow the experience of intensity of football like never before. The Guardian (U.K.) mentioned that FIFA 15 is doing what EA has always wanted to do, as it plays in a way that makes gamers feel like they belong on the pitch. The game includes some good-looking player faces, described Game Informer (USA).
Pacific Biosciences of California (NASDAQ:PACB) announced that a leading genome sequencing services provider Macrogen has selected the PacBio SMRT® (Single Molecule, Real Time) Sequencing platform to develop high quality de novo ‘human genome references’ for the Asian population. In addition, Macrogen will also use the two RS II DNA Sequencing Systems of the company for other sequencing applications, which can’t be done effectively with ‘short read’ sequencing technologies. Pacific Biosciences CEO, Michael Hunkapiller expressed, it is great that Macrogen decided to adopt PacBio technology for more accurate and relevant reference genomes. The PacBio RS II System can generate high-quality reference genomes better than or as good as Sanger sequencing.